NR4A1 and breast carcinoma: The molecular subtypes of breast cancer have been shown to predict the clinical outcome, and in particular breast cancers expressing hormone receptors (luminal A) have a more favorable prognosis, while women with basal-like breast cancers (including most of the triple-negative tumors) had shorter relapse-free survival times than women with other types of breast cancer [2].